Corvus Pharmaceuticals, Inc. (CRVS)

Corvus Pharmaceuticals, Inc. (CRVS) Healthcare & Pipeline Overview

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical firm focused on immuno-oncology, developing therapies like Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody targeting cancers. With strategic collaborations and a pipeline of investigational medicines, Corvus aims to address unmet needs in cancer treatment within the competitive biotechnology landscape.

What Is the Investment Thesis for CRVS?

Corvus Pharmaceuticals presents a notable research candidate given its focus on immuno-oncology and a promising pipeline of clinical-stage assets. The lead product candidate, Mupadolimab (CPI-006), targeting CD73, has shown potential in early-stage trials for non-small cell lung cancer and head and neck cancers. Successful advancement through clinical trials and potential FDA approval could significantly drive revenue growth. The company's strategic collaboration with Angel Pharmaceuticals also provides a pathway for expanding its pipeline and market reach. However, the company faces risks associated with clinical trial outcomes, regulatory hurdles, and competition from other immuno-oncology therapies. With a market cap of $1.28B and no current revenue, the company's valuation is heavily dependent on the successful development and commercialization of its pipeline.

Based on FMP financials and quantitative analysis

CRVS Key Highlights

• Mupadolimab (CPI-006) is in Phase Ib/II clinical trials for non-small cell lung cancer and head and neck cancers, demonstrating potential in early-stage trials.
• CPI-818, a covalent inhibitor of ITK, is in Phase I/Ib clinical trials for various malignant T-cell lymphomas, targeting the proliferation of malignant T-cells.
• Ciforadenant (CPI-444), an oral A2A receptor antagonist, is in Phase II clinical trials for patients with advanced or refractory renal cell cancer.
• Strategic collaboration with Angel Pharmaceuticals to develop its pipeline of targeted investigational medicines.
• Market capitalization of $1.28B reflects investor confidence in the company's pipeline and immuno-oncology focus.

Who Are CRVS's Competitors?

CRVS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CRVS's Key Strengths?

• Promising pipeline of clinical-stage immuno-oncology assets.
• Novel targets, such as CD73 and ITK, with potential for unique advantages.
• Strategic collaboration with Angel Pharmaceuticals.
• Experienced management team.

What Are CRVS's Weaknesses?

• Clinical-stage company with no current revenue.
• High dependence on successful clinical trial outcomes.
• Limited financial resources compared to larger pharmaceutical companies.
• Concentration of pipeline on a few key assets.

What Could Drive CRVS Stock Higher?

• Data readout from Phase Ib/II clinical trial of Mupadolimab (CPI-006) in non-small cell lung cancer and head and neck cancers expected in Q4 2026.
• Initiation of Phase III clinical trial for Mupadolimab (CPI-006) pending positive Phase Ib/II results.
• Enrollment and progress in Phase I/Ib clinical trial of CPI-818 in various malignant T-cell lymphomas.
• Enrollment and progress in Phase II clinical trial of Ciforadenant (CPI-444) in patients with advanced or refractory renal cell cancer.

What Are the Key Risks for CRVS?

• Negative return on equity (-38.9%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or delays for any of the pipeline assets.
• Regulatory hurdles and delays in approval processes.
• Competition from other immuno-oncology therapies.
• Patent expirations and generic competition.
• Dependence on successful clinical trial outcomes for valuation.

What Are the Growth Opportunities for CRVS?

• Mupadolimab (CPI-006) Development: The continued development of Mupadolimab (CPI-006) represents a significant growth opportunity. Successful completion of Phase Ib/II clinical trials for non-small cell lung cancer and head and neck cancers, followed by positive Phase III results, could lead to FDA approval and commercialization. The market for lung cancer and head and neck cancer treatments is substantial, with a global market size estimated to be in the billions of dollars. This timeline is ongoing, with trial results expected in the next 1-3 years.
• CPI-818 Expansion: The expansion of CPI-818's clinical development into additional T-cell lymphoma subtypes and potentially other hematological malignancies represents another growth opportunity. Positive results from the ongoing Phase I/Ib trial could lead to further clinical trials and eventual commercialization. The market for T-cell lymphoma treatments is growing, driven by the need for more effective therapies with fewer side effects. This expansion could unfold over the next 2-4 years.
• Ciforadenant (CPI-444) Advancement: Advancing Ciforadenant (CPI-444) through clinical trials for renal cell cancer and potentially other solid tumors offers a growth avenue. Positive Phase II trial results could pave the way for Phase III trials and eventual FDA approval. The renal cell cancer market is competitive but has significant unmet needs, particularly in patients with advanced or refractory disease. This advancement is expected to progress over the next 2-3 years.
• Strategic Collaborations: Pursuing additional strategic collaborations with other pharmaceutical or biotechnology companies could provide access to new technologies, funding, and expertise. Collaborations can accelerate the development and commercialization of Corvus's pipeline assets and expand its market reach. These collaborations could be established within the next 1-2 years.
• Preclinical Pipeline Development: Advancing the preclinical pipeline, including CPI-182 and CPI-935, into clinical development represents a longer-term growth opportunity. These assets target novel pathways involved in inflammation, myeloid suppression, and fibrosis, potentially addressing unmet needs in various diseases. The development of these assets could unfold over the next 3-5 years.

What Opportunities Does CRVS Have?

• Successful completion of clinical trials and FDA approval of pipeline assets.
• Expansion of pipeline through internal development and strategic collaborations.
• Penetration of new markets and indications.
• Potential for breakthrough therapies in immuno-oncology.

What Threats Does CRVS Face?

• Clinical trial failures or delays.
• Regulatory hurdles and delays in approval processes.
• Competition from other immuno-oncology therapies.
• Patent expirations and generic competition.

What Are CRVS's Competitive Advantages?

• Proprietary technology platform for developing immuno-oncology therapies.
• Strong intellectual property portfolio protecting their pipeline assets.
• Experienced management team with a track record of success in drug development.
• Strategic collaborations with leading pharmaceutical companies.

What Does CRVS Do?

Corvus Pharmaceuticals, Inc., founded in 2014 and based in Burlingame, California, is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of innovative immuno-oncology therapies. The company's primary focus is on creating novel treatments that harness the body's immune system to fight cancer. Corvus's lead product candidate, Mupadolimab (CPI-006), is an anti-CD73 monoclonal antibody currently undergoing Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. This therapy aims to block the activity of the CD73 enzyme, which is often overexpressed in tumors and contributes to immune suppression. In addition to Mupadolimab, Corvus is developing CPI-818, a covalent inhibitor of ITK, in Phase I/Ib clinical trials for various malignant T-cell lymphomas. CPI-818 is designed to inhibit the proliferation of malignant T-cells, offering a targeted approach to treating these cancers. The company's pipeline also includes Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor, which is in Phase II clinical trials for patients with advanced or refractory renal cell cancer. Furthermore, Corvus has preclinical stage products such as CPI-182, an antibody designed to block inflammation and myeloid suppression, and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals has a strategic collaboration with Angel Pharmaceuticals to further develop its pipeline of targeted investigational medicines, expanding its reach and capabilities in the biopharmaceutical space.

What Products and Services Does CRVS Offer?

• Develop immuno-oncology therapies to treat cancer.
• Focus on harnessing the body's immune system to fight cancer.
• Develop monoclonal antibodies and small molecule inhibitors.
• Conduct clinical trials to evaluate the safety and efficacy of their therapies.
• Collaborate with other companies to expand their pipeline and market reach.
• Target novel pathways, such as CD73 and ITK, in cancer treatment.

How Does CRVS Make Money?

• Develop and commercialize immuno-oncology therapies.
• Generate revenue through sales of approved products.
• Collaborate with other companies to share development costs and royalties.
• Out-license their technologies to other companies for further development and commercialization.

What Industry Does CRVS Operate In?

Corvus Pharmaceuticals operates within the rapidly evolving immuno-oncology sector, which is experiencing significant growth due to advancements in cancer immunotherapy. The market is characterized by intense competition among pharmaceutical and biotechnology companies developing novel therapies that harness the immune system to fight cancer. Key trends include the development of checkpoint inhibitors, adoptive cell therapies, and oncolytic viruses. Corvus differentiates itself through its focus on targeting novel pathways, such as CD73 and ITK, which may offer unique advantages in specific cancer types. The global immuno-oncology market is projected to reach billions of dollars in the coming years, driven by increasing cancer incidence and the demand for more effective and less toxic treatments.

Who Are CRVS's Key Customers?

• Patients with cancer who are seeking new treatment options.
• Oncologists who are treating patients with cancer.
• Hospitals and clinics that provide cancer care.
• Pharmaceutical companies that are interested in licensing or acquiring their technologies.

Company Profile

Corvus Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in South San Francisco, US. The company is led by CEO Richard A. Miller. CRVS has traded publicly since 2016.

How Corvus Pharmaceuticals, Inc. Is Valued

Corvus Pharmaceuticals, Inc. carries a market capitalization of $1.28B, placing it in the small-cap category. Relative to its peer group, CRVS's quantitative score of 65/100 is below the peer average of 84/100.

ROE -39%Key Financial Metrics

Return on equity for Corvus Pharmaceuticals, Inc. stands at -38.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -17.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -2.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 19.81 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -3.3%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 2/9Financial Health

Corvus Pharmaceuticals, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 59.57 places it in the safe zone, indicating low near-term bankruptcy risk.

FY2026 estForward Outlook

Wall Street analysts project Corvus Pharmaceuticals, Inc. revenue of about $-200K for fiscal 2026, with EPS near $-0.68. The estimate reflects 4 contributing analysts.

CRVS Financials

CRVS Latest News

CRVS Analyst Consensus

CRVS MoonshotScore

CRVS Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources